Ulcerative colitis (UC)

What changes during this transition

Ulcerative colitis is a chronic inflammatory bowel disease characterized by continuous mucosal inflammation extending proximally from the rectum, presenting with bloody diarrhea, urgency, and tenesmus, classified by extent per Montreal (E1 proctitis / E2 left-sided / E3 pancolitis). UC carries real long-term morbidity — primary sclerosing cholangitis (PSC) association in a meaningful minority, colorectal cancer risk that scales with disease duration + extent + PSC status (with surveillance beginning 8 years post-diagnosis, earlier for PSC or extensive disease, via chromoendoscopy or HD-WLE with targeted biopsies), and the rare-but-fatal toxic megacolon emergency. Modern management runs on treat-to-target frameworks (ACG 2019, AGA 2020, ECCO 2022, with Crohn's & Colitis Foundation patient-facing alignment) — combining clinical activity assessment, biomarkers (CRP, fecal calprotectin), and endoscopic confirmation (Mayo endoscopic subscore 0-1 mucosal healing), increasingly with histologic remission as a tertiary target. The therapeutic ladder is: 5-ASA optimization (mesalamine, sulfasalazine, balsalazide, olsalazine — Tier 1 mild-moderate, often under-optimized before escalation), corticosteroids for induction (not maintenance), thiopurines (AZA, 6-MP) for maintenance, anti-TNF (infliximab, adalimumab, golimumab/Simponi), anti-integrin (vedolizumab/Entyvio — gut-selective), anti-IL-12/23 (ustekinumab — FDA Oct 2019 UC via UNIFI), the IL-23p19 selective biologics (mirikizumab/Omvoh FDA Oct 2023 via LUCENT-1/2; guselkumab/Tremfya FDA Sep 2024 via QUASAR), JAK inhibitors (tofacitinib/Xeljanz FDA 2018 via OCTAVE with ORAL Surveillance black-box for cardiovascular events + malignancy + thromboembolism; upadacitinib/Rinvoq FDA March 2022 via U-ACHIEVE / U-ACCOMPLISH), and S1P receptor modulators (ozanimod/Zeposia FDA May 2021 via True North; etrasimod/Velsipity FDA Oct 2023 via ELEVATE UC 12/52). Colectomy with ileal pouch-anal anastomosis remains definitive for medically-refractory disease, dysplasia, cancer, or toxic megacolon. The IL-23p19 paradigm is the single most important context for any UC peptide conversation today. Mirikizumab (Omvoh, FDA October 2023, LUCENT-1/2) and guselkumab (Tremfya, FDA September 2024 for UC via QUASAR) joined ustekinumab to give clinicians three IL-23-axis biologics with distinct selectivity profiles. Concurrently the small-molecule oral revolution arrived: tofacitinib carrying the ORAL Surveillance black-box for cardiovascular events + malignancy + thromboembolism in at-risk populations, upadacitinib as the more selective JAK1 inhibitor, ozanimod and etrasimod bringing S1P receptor modulation. Where Juno's library fits — narrowly and with deliberate non-elevation. The five drafted substrate entries (BPC-157, KPV, Thymosin alpha-1, Larazotide, Selank) exist for honest /ask answers when users probe. BPC-157's 'gut healer' framing rests on the Sikiric Croatia rodent colitis corpus — preclinical only. KPV has the most mechanistically plausible UC case in this batch (PepT1-mediated NF-κB suppression, Dalmasso 2008) but the human UC trial base is essentially absent. Thymosin alpha-1's hepatitis-B Tier 1 registered indication does not propagate to UC per Rule 6, and the immune-direction concern is real. Larazotide's CeD-LIFT Phase 3 in celiac was terminated 2022 after failing primary endpoint; tight-junction modulation in celiac doesn't predict UC efficacy. Selank addresses the genuine 25-35%+ anxiety+depression comorbidity but doesn't engage UC disease activity. Deploying peptides as escalation-avoidance against a fast-moving standard-of-care ladder accumulates inflammatory burden + dysplasia risk + cumulative steroid exposure that mucosal healing on appropriate therapy could have prevented. The honest editorial frame: IBD gastroenterology coordination, 5-ASA optimization before escalation, the modern biologic + small-molecule ladder driven by treat-to-target with clinical + biomarker + endoscopic + histologic confirmation, CRC surveillance from 8 years (earlier for PSC/extensive), and IBD-specific behavioral health integration for anxiety overlay drive outcomes.